PharmaEssentia Initiates Phase 3b Trial of ropeginterferon alfa-2b-njft Investigating New Dosing Regimen for Patients with Polycythemia Vera (PV)

Press/Media

Period	3 May 2023

Media coverage

Title	PharmaEssentia Initiates Phase 3b Trial of ropeginterferon alfa-2b-njft Investigating New Dosing Regimen for Patients with Polycythemia Vera (PV)
Media name/outlet	India Pharma News
Country/Territory	India
Date	3/05/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=6857-9YR1-DXMP-K046-00000-00
Persons	John Mascarenhas, Jun Wang